A股异动丨皓元医药跌约4% 股东苏信基金拟减持不超3%公司股份

Core Viewpoint - Haoyuan Pharmaceutical (688131.SH) experienced a decline of 3.94% to 52.16 yuan during trading, following an announcement regarding a significant share reduction by a major shareholder [1] Group 1: Company Announcement - The shareholder, Su Min Investment Junxin (Shanghai) Industrial Upgrade and Technology Innovation Equity Investment Partnership (Limited Partnership), plans to reduce its holdings by up to 6,362,959 shares [1] - The proposed reduction represents a maximum of 3% of the company's current total share capital [1] - The reduction period is set from August 29, 2025, to November 28, 2025 [1]